Genetic variation in sodium glucose co‐transporter 1 and cardiac structure and function at middle age

The effects of inhibition of sodium glucose cotransporter (SGLT)‐1, as opposed to SGLT2, on cardiovascular structure and function are not well known. We assessed the associations of a missense genetic variant of SGLT1 with cardiac structure and function.

[1]  B. Merkely,et al.  Effects of SGLT2 Inhibitors beyond Glycemic Control—Focus on Myocardial SGLT1 , 2021, International journal of molecular sciences.

[2]  Deepak L. Bhatt,et al.  Does SGLT1 Inhibition Add Benefit to SGLT2 Inhibition in Type 2 Diabetes Mellitus? , 2021, Circulation.

[3]  S. Solomon,et al.  Association of Left Ventricular Systolic Function With Incident Heart Failure in Late Life. , 2021, JAMA cardiology.

[4]  W. März,et al.  Genetic Variation in Sodium‐glucose Cotransporter 2 and Heart Failure , 2021, Clinical pharmacology and therapeutics.

[5]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. , 2020, The New England journal of medicine.

[6]  Deepak L. Bhatt,et al.  Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. , 2020, The New England journal of medicine.

[7]  B. Merkely,et al.  Characterization of left ventricular myocardial sodium-glucose cotransporter 1 expression in patients with end-stage heart failure , 2020, Cardiovascular Diabetology.

[8]  Ferhaan Ahmad,et al.  Cardiac Sodium-Glucose Co-Transporter 1 (SGLT1) is a Novel Mediator of Ischemia/Reperfusion Injury. , 2019, Cardiovascular research.

[9]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[10]  Helen E. Parkinson,et al.  The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019 , 2018, Nucleic Acids Res..

[11]  E. Boerwinkle,et al.  Genetic Variants in SGLT1, Glucose Tolerance, and Cardiometabolic Risk , 2018, Journal of the American College of Cardiology.

[12]  K. Connelly,et al.  Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction , 2018, Cardiovascular Diabetology.

[13]  E. Laurila,et al.  Genetic determinants of circulating GIP and GLP-1 concentrations. , 2017, JCI insight.

[14]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[15]  Mitchell J. Machiela,et al.  LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants , 2015, Bioinform..

[16]  Ferhaan Ahmad,et al.  Transgenic Knockdown of Cardiac Sodium/Glucose Cotransporter 1 (SGLT1) Attenuates PRKAG2 Cardiomyopathy, Whereas Transgenic Overexpression of Cardiac SGLT1 Causes Pathologic Hypertrophy and Dysfunction in Mice , 2014, Journal of the American Heart Association.

[17]  P. Donnelly,et al.  Inference of population structure using multilocus genotype data. , 2000, Genetics.

[18]  S B Hulley,et al.  CARDIA: study design, recruitment, and some characteristics of the examined subjects. , 1988, Journal of clinical epidemiology.